Compounds > chloroquine

chloroquine and candesartan

chloroquine has been researched along with candesartan in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Ma, C; Wang, J1
Huang, YY; Li, Z; Lin, Y; Liu, R; Luo, HB; Wang, X; Zhan, CG1

Reviews

1 review(s) available for chloroquine and candesartan

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

4 other study(ies) available for chloroquine and candesartan

ArticleYear
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
    Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19

    Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship

2008
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors.
    Proceedings of the National Academy of Sciences of the United States of America, 2021, 02-23, Volume: 118, Issue:8

    Topics: Acetates; Atazanavir Sulfate; Benzimidazoles; Biphenyl Compounds; Chloroquine; COVID-19 Drug Treatment; Cyclopropanes; Dipyridamole; Humans; Oxytetracycline; Pharmaceutical Preparations; Protease Inhibitors; Quinolines; SARS-CoV-2; Sulfides; Tetrazoles

2021
Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors.
    Proceedings of the National Academy of Sciences of the United States of America, 2021, 02-23, Volume: 118, Issue:8

    Topics: Acetates; Atazanavir Sulfate; Benzimidazoles; Biphenyl Compounds; Chloroquine; COVID-19 Drug Treatment; Cyclopropanes; Dipyridamole; Humans; Oxytetracycline; Protease Inhibitors; Quinolines; Reproducibility of Results; SARS-CoV-2; Sulfides; Tetrazoles

2021